Cerezyme
Gaucher Disease Type 3
Genzyme, a Sanofi CompanyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Gaucher Disease Type 3 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Velaglucerase Alfa Baylor Research Institute | Phase 4 | BB |
Eliglustat Genzyme, a Sanofi Company | Phase 2 | CCC |
Venglustat Genzyme, a Sanofi Company | Phase 2 | CCC |
Vgn-R08B Shanghai Vitalgen BioPharma Co., Ltd. | Phase 1/2 | CCC |
Same molecule, other indications
Cerezyme is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →